Results 1 to 10 of about 29,938 (169)

Colistin Sensitivity and Factor H-Binding Protein Expression among Commensal Neisseria Species

mSphere, 2021
This study highlights the need for further work to accurately determine the pharyngeal carriage prevalence of NeisseriaN.
Stephen A. Clark, Steve Gray, Adam Finn, Ray Borrow   +3 more
doaj   +1 more source

Vaccination Coverage among Immunocompromised Patients in a Large Health Maintenance Organization: Findings from a Novel Computerized Registry

Vaccines, 2022
Immune-compromised patients (IPs) are at high risk for infections, some of which are preventable by vaccines. Specific vaccines are recommended for IP; however, the vaccination rate is suboptimal.
Shirley Shapiro Ben David, Iris Goren, Vered Mourad, Amos Cahan   +3 more
doaj   +1 more source

Herd Protection against Meningococcal Disease through Vaccination

Microorganisms, 2020
Reduction in the transmission of Neisseria meningitidis within a population results in fewer invasive disease cases. Vaccination with meningococcal vaccines composed of high weight capsular polysaccharide without carrier proteins has minimal effect ...
Stephen A. Clark, Ray Borrow
doaj   +1 more source

Analysis of Intestinal and Nasopharyngeal Microbiota of Children with Meningococcemia in Pediatric Intensive Care Unit: INMACS-PICU Study

Diagnostics, 2023
Microbiota composition might play a role in the pathophysiology and course of sepsis, and understanding its dynamics is of clinical interest. Invasive meningococcal disease (IMD) is an important cause of community-acquired serious infection, and there is
Gurkan Bozan, Vicente Pérez-Brocal, Kaan Aslan, Eylem Kiral, Esra Sevketoglu, Mutlu Uysal Yazici, Ebru Azapagasi, Tanil Kendirli, Serhat Emeksiz, Oguz Dursun, Dincer Yildizdas, Ayse Berna Anil, Nihal Akcay, Hasan Serdar Kihtir, Merve Havan, Nazan Ulgen Tekerek, Faruk Ekinci, Omer Kilic, Andres Moya, Ener Cagri Dinleyici   +19 more
doaj   +1 more source

Health Technology Assessment for Vaccines Against Rare, Severe Infections: Properly Accounting for Serogroup B Meningococcal Vaccination's Full Social and Economic Benefits

Frontiers in Public Health, 2020
The high price of new generations of vaccines relative to their predecessors has become an important consideration in debates over whether the benefits of the new vaccines justify their costs.
Andrew Stawasz, Andrew Stawasz, Liping Huang, Paige Kirby, David Bloom, David Bloom   +5 more
doaj   +1 more source

Risk factors for carriage of meningococcus in third-level students in Ireland: an unsupervised machine learning approach

Human Vaccines & Immunotherapeutics, 2021
The aim of this study was to examine the risk factors for pharyngeal carriage of meningococci in third-level students using an unsupervised machine learning approach.
Richard J. Drew, Desirée Bennett, Sinéad O’Donnell, Robert Mulhall, Robert Cunney   +4 more
doaj   +1 more source

Preventing invasive meningococcal disease in early infancy

Human Vaccines & Immunotherapeutics, 2022
This review considers the pathogenesis, diagnosis, and epidemiology of invasive meningococcal disease in infants, to examine and critique meningococcal disease prevention in this population through vaccination.
Jessica Presa, Lidia Serra, Catherine Weil-Olivier, Laura York   +3 more
doaj   +1 more source

Invasive meningococcal disease in patients with complement deficiencies: a case series (2008–2017)

BMC Infectious Diseases, 2019
Background To describe patients with inherited and acquired complement deficiency who developed invasive meningococcal disease (IMD) in England over the last decade. Methods Public Health England conducts enhanced surveillance of IMD in England.
Shamez N. Ladhani, Helen Campbell, Jay Lucidarme, Steve Gray, Sydel Parikh, Laura Willerton, Stephen A. Clark, Aiswarya Lekshmi, Andrew Walker, Sima Patel, Xilian Bai, Mary Ramsay, Ray Borrow   +12 more
doaj   +1 more source

Summary of the NACI Statement on the Use of Bivalent Factor H Binding Protein Meningococcal Serogroup B (MenB-fHBP) Vaccine for the Prevention of Meningococcal B Disease

Canada Communicable Disease Report, 2020
Background: Trumenba™, a bivalent, factor-H binding protein meningococcal serogroup B (MenB-fHBP) vaccine was authorized for use in Canada in October 2017 for the prevention of invasive meningococcal disease (IMD) caused by Neisseria meningitidis ...
Robyn Harrison, Robert Stirling, Oliver Baclic, Wendy Vaudry   +3 more
doaj   +1 more source

Insights on Population Structure and Within-Host Genetic Changes among Meningococcal Carriage Isolates from U.S. Universities

mSphere, 2020
In 2015 and 2016, meningococcal carriage evaluations were conducted at two universities in the United States following mass vaccination campaigns in response to Neisseria meningitidis serogroup B (NmB) disease outbreaks.
Sandeep J. Joseph, Nadav Topaz, How-Yi Chang, Melissa J. Whaley, Jeni T. Vuong, Alexander Chen, Fang Hu, Susanna E. Schmink, Laurel T. Jenkins, Lorraine D. Rodriguez-Rivera, Jennifer D. Thomas, Anna M. Acosta, Lucy McNamara, Heidi M. Soeters, Sarah Mbaeyi, Xin Wang   +15 more
doaj   +1 more source